Streetwise Reports' Article Archives — October 2020 back to current month (26)
Shares of Acadia Healthcare reached a new 52-week high after the company reported Q3/20 financial results that included a 7.5% YoY increase in revenue at its U.S. health facilities.
Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial.
Exact Sciences Corp. shares reached a new 52-week high after the maker of cancer screening test Cologuard reported Q3/20 financial results that included a greater than 86% increase in year-over-year revenue.
Mirati Therapeutics' shares reached a new 52-week high after the company reported preliminary data for Adagrasib (MRTX849) demonstrated durable anti-tumor activity in its non-small cell lung cancer and colorectal cancer studies.
ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic.
Shares of Align Technology traded 35% higher and climbed to a new 52-week high after the company reported Q3/20 financial results that included a 20.9% YoY increase in net revenues.
Revive Therapeutics will use these products in future studies and clinical trials.
Aptinyx shares set a new 52-week high price after the company reported statistically significant, top-line data from its Phase 2 Study of NYX-783 in patients diagnosed with post-traumatic stress disorder.
Biospecifics Technologies shares traded 45% higher after the company reported that it agreed to be acquired by Endo Pharmaceuticals for $88.50 per share in an all cash transaction.
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co.
Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue.
Five sites in Australia and New Zealand are participating in this study of Algernon Pharmaceuticals' drug.
Avivagen Inc. reported that it has received a record purchase order for its OxC-beta™ product from UNAHCO.
The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report.
Shares of Allscripts Healthcare Solutions traded 30% higher after the company reported it has agreed to sell its CarePort Health business to WellSky Corp. for $1.35 billion.
Altimmune Inc. shares traded 12% higher after the company published preclinical studies conducted together with the University of Alabama at Birmingham for AdCOVID, its intranasal COVID-19 vaccine candidate.
CareDx shares established a new 52-week high after the company reported that preliminary revenue in Q3/20 increased 57% year-over-year to $53.0 million.
StreetSmart Live! Presents Algernon Pharmaceuticals (10/08/2020)
Algernon Pharmaceuticals CEO Christopher Moreau and guests fund manager Steve Palmer, Dr. Mark Swaim and Tony Pullen discuss the company's upcoming catalysts and events.
The study data and potential near-term catalysts for Enlivex Therapeutics are covered in an H.C. Wainwright & Co. report.
Avivagen reports that it has gained both new customers and increased access to prospective ones.
Ocular Therapeutix shares reached a new 52-week high after the company reported that preliminary net product revenue increased to $5.8-5.9 million during Q3/20, representing a more than 250% increase over the previous quarter.
Algernon Pharmaceuticals expects completion of the clinical trial next month and data readout by year-end.
Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash.
Shares of American Renal Associates traded 67% higher and set a new 52-week high after the company reported that it has entered into a definitive agreement to be acquired by a Nautic Partners LLC affiliate for $11.50 per share in cash.
CloudMD: The Best Bet in Telehealth? (10/01/2020)
Peter Epstein of Epstein Research reviews the reasons he believes CloudMD is poised for substantial growth compared to peers.
Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|